Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria
Patients with thrombosis at an unusual site will need to be explored for rare causes of thrombosis. Two of these rare causes include myeloproliferative neoplasms (MPNs) and
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates
Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT
For patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capable of eradicating disease-related mutant hematopoietic cells and establishing normal donor hematopoiesis.
How is transfusion dependence evolving in anemia treatment in MDS?
A roundtable discussion on anemia management in
Jane Biehl: Moving Slower and Slower After Myelodysplastic Syndrome
I have honestly been frustrated lately. I am slowing down increasingly, and it has even become noticeable to others. I wrote an article in November about how nice it was to slow down and smell the roses. But now it seems like too much.
Maintenance Therapy in AML: What Is the Future Potential?
Therapeutic Advances and Future of Therapy in Acute Myeloid Leukemia
What are some of the new therapies discussed at ASH 2024?
A roundtable discussion on anemia management in
Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications
Key Points
The ICC and WHO5 differently classify 64% of TP53-mutated disease due to distinct criteria for multihit TP53 mutations and TP53-mutated AML.